




A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort

Manuel Francisco Ugarte-Gil ^{1,2}, Rocio Violeta Gamboa-Cardenas,^{1,2} Cristina Reátegui-Sokolova ^{1,3}, Victor Román Pimentel-Quiroz ^{1,2}, Mariela Medina,¹ Claudia Elera-Fitzcarrald,^{1,4} Zoila Rodriguez-Bellido,^{1,5} Cesar Augusto Pastor-Asurza,^{1,5} Risto Alfredo Perich-Campos,^{1,5} Graciela S Alarcón^{6,7}

To cite: Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, *et al.* A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort. *Lupus Science & Medicine* 2023;**10**:e000874. doi:10.1136/lupus-2022-000874

These analyses were conducted as part of the PhD programme requirements at Universidad Nacional Mayor de San Marcos where MFU-G is a candidate. Preliminary results were presented at the 2022 EULAR Congress. Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui Sokolova C, *et al.* A better self-efficacy is predictive of better health-related quality of life (HRQoL) in systemic lupus erythematosus patients. Data from a Latin American Mestizo Cohort. *Ann Rheum Dis* 2022;**81**:647.

Received 4 December 2022
Accepted 27 January 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Manuel Francisco Ugarte-Gil; mugarte@cientifica.edu.pe

ABSTRACT

Objective To determine the possible predictive value of self-efficacy on health-related quality of life (HRQoL) in patients with SLE.

Methods Patients with SLE from the Almenara Lupus Cohort were included. Self-efficacy was ascertained with the six domains from the Patient-Reported Outcomes Measurement Information System (PROMIS) self-efficacy for managing chronic conditions. For PROMIS domains, a score of 50 is the average for a clinical population (people with a chronic condition), a higher score indicates that the respondent has greater self-efficacy. HRQoL was ascertained with the physical and mental component summary (PCS and MCS) measures of the Short-Form 36 (SF-36). Generalised estimating equations were performed, using as outcome the PCS or MCS in the subsequent visit, and the self-efficacy domain in the previous visit; multivariable models were adjusted for possible confounders. The confounders were measured in the same visit as the self-efficacy domain.

Results Two-hundred and nine patients for a total of 564 visits were included; 194 (92.8%) patients were women and mean age at diagnosis was 36.4 (14.0) years. In the multivariable models, a better PCS was predicted by a better self-efficacy for managing symptoms, managing medications and treatments and managing social interactions and general self-efficacy; a better MCS was predicted by a better self-efficacy for managing daily activities, managing symptoms, managing medications and treatments and managing social interactions.

Conclusion A better self-efficacy is predictive of subsequent better HRQoL, even after adjustment for possible confounders. These results should encourage clinicians to develop strategies to improve self-efficacy in patients with SLE.

INTRODUCTION

Self-efficacy is the belief that one can carry out a behaviour necessary to reach a desired

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Health-related quality of life (HRQoL) has been associated with several sociodemographic factors, but its association with disease activity and damage is still controversial.
- ⇒ Self-efficacy is the individual's confidence in the ability to perform specific tasks.

WHAT THIS STUDY ADDS

- ⇒ A better self-efficacy was associated with a subsequent better HRQoL.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study reinforces the need to develop effective strategies that improve self-efficacy.

goal.¹ Additionally, for patients with chronic conditions, self-efficacy for managing them is defined as an individual's confidence in his/her ability to successfully perform specific tasks or behaviours related to one's health in a variety of situations.²

The National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) was constituted to develop and evaluate a set of publicly available, efficient and flexible measurements of patient-reported outcomes (PROs).³ The PROMIS self-efficacy for managing chronic conditions includes five domains: self-efficacy for managing daily activities, self-efficacy for managing symptoms, self-efficacy for managing medications and treatments, self-efficacy for managing emotions and self-efficacy for managing social interactions.⁴ Additionally, the PROMIS general self-efficacy

was developed to measure global self-efficacy.⁵ All domain measures of the PROMIS self-efficacy for managing chronic conditions's instrument had a Cronbach's α ranging from 0.90 to 0.95. All short forms correlated highly with the full item bank ($r > 0.90$). All measures have demonstrated good item-total correlations ($r > 0.55$ for the eight-item short forms).⁴ The general PROMIS self-efficacy had a Cronbach's α of 0.88.⁵ PROMIS self-efficacy for managing chronic conditions correlated with other related measures as physical function, fatigue, depression, anxiety, global mental health, global physical health, disease severity and disability.⁴ The general PROMIS self-efficacy correlated with life orientation test, generalised expectancy for success scale, NIH toolbox self-efficacy item bank and PROMIS global physical and mental health.⁵

Health-related quality of life (HRQoL) is affected in patients with SLE, and it is influenced by the patient's age, poverty, educational level, behavioural issues, some clinical manifestations and comorbidities.⁶ However, the association between HRQoL and disease activity or damage has not been consistently reported, suggesting that factors related to the patient could be more relevant than those related to the disease itself. One of these factors is self-efficacy, as it measures the patients' ability to perform specific tasks. In older adults, self-efficacy has been shown to be a mediator between frailty and HRQoL, suggesting that improvements on one will result in improvements on the other.⁷ In neurological disorders, it has been shown that self-efficacy for managing chronic conditions is a better predictor of better mental health, global health and lower disability rates than either disease severity or diagnosis.⁸ However, the impact of self-efficacy on HRQoL has been scarcely evaluated in SLE.

The aim of this study was to evaluate the impact of self-efficacy on HRQoL in our patients with SLE.

METHODS

The Almenara Lupus Cohort has been previously described.⁹ In short, this cohort was started in 2012 at the Rheumatology Department of the Hospital Guillermo Almenara Irigoyen in Lima, Peru. Patients who signed the informed consent were recruited and followed every 6 months. Evaluations included an interview, medical records review, physical examination and laboratory tests. For these analyses, we have included those patients with at least two visits between October 2018 and February 2020.

SLE was defined using the 1997 revised American College of Rheumatology (ACR) criteria.¹⁰ Demographic data included were gender, age at diagnosis, socioeconomic status according to the Graffar's method¹¹ and educational level, defined as years of formal education. Disease activity was ascertained using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K).¹¹ Damage was ascertained with the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI).¹² HRQoL was ascertained using the Short-Form

36 (SF-36).¹³ The SF-36 includes two main components, physical and mental component summary (PCS and MCS) measures as well as the following eight domains (physical functioning, role physical, role emotional, fatigue, emotional health, social functioning, bodily pain and general health). Therapeutic variables included were current prednisone dose, antimalarials and immunosuppressive drugs use (including methotrexate, azathioprine, leflunomide, mycophenolate mofetil, calcineurin inhibitors, cyclophosphamide and rituximab); the later were recorded as current, past or never administered.

Self-efficacy was ascertained with the five domains of the PROMIS self-efficacy for managing chronic conditions: managing daily activities, managing symptoms, managing medications and treatments, managing emotions and managing social interactions⁴ and the PROMIS general self-efficacy.⁵ Self-efficacy for managing daily activities included the assessment of the subject's confidence in performing various activities of daily living without assistance; self-efficacy for managing symptoms included assessment of the subject's level of confidence to manage/control their symptoms, to manage their symptoms in different settings and to keep their symptoms from interfering with work, sleep, relationships or recreational activities; self-efficacy for managing medication and treatments included assessment of the subject's confidence in managing medication schedules of different complexity; self-efficacy for managing emotions included assessment of the subject's level of confidence to manage/control symptoms of anxiety, depression, helplessness, discouragement, frustration, disappointment and anger and self-efficacy for managing social interactions included assessment of the subject's confidence in participation in social activities and getting help when necessary.⁴ Each of the five domains of the PROMIS self-efficacy for managing chronic conditions has eight items with raw scores ranging from 8 to 40 whereas PROMIS general self-efficacy has four items with a raw score ranging from 4 to 20. All raw scores are converted into T-scores metrics in which 50 is the average and 10 is the SD; for a clinical population (people with a chronic condition), a higher score indicates that the respondent has greater self-efficacy, for example, a score of 60 is 1 SD higher than the mean of the reference population.

The PROMIS self-efficacy measures were translated following the WHO Process of Translation and Adaptation of Instruments.¹⁴ The forward translation was done by a bilingual rheumatologist, whose mother's tongue is Spanish. Then, these translations were evaluated by an expert panel including four bilingual rheumatologists to identify and resolve the translation's inadequate expressions/concepts. Then, the back-translation was done by a bilingual health professional whose mother's tongue is English and who had no prior knowledge of the questionnaire. Then, the draft was tested in 10 patients with SLE using face-to-face interviews to evaluate clarity and understanding.

Cronbach's α for the PROMIS self-efficacy for managing chronic conditions were for managing daily activities 0.94, for managing symptoms 0.93, for managing medications and treatments 0.85, for managing emotions 0.95 and for managing social interactions 0.90 and for general PROMIS self-efficacy 0.94.

Statistical analyses

Categorical variables are reported as numbers and percentages, numerical variables as means and SD. The correlation between the self-efficacy's domains was evaluated using Spearman's rho. Due to the number of variables included in the multivariable model, at least 138 patients needed to be included for the analyses to be meaningful.¹⁵

Generalised estimating equations were performed, using as outcome the PCS or MCS in the subsequent visit to the one in which self-efficacy had been assessed; multivariable models were adjusted for possible confounders (age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SDI, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and PCS or MCS in the previous visit). All the confounders were measured in the same visit than the self-efficacy domain.

As alternative analyses, each domain of the SF-36 was included as an outcome.

A $p < 0.05$ was considered significant in all analyses. All analyses were performed using SPSS V.28.0 (IBM, Chicago, Illinois, USA).

RESULTS

Two-hundred and nine patients for a total of 564 visits were included, with a mean (SD) number of follow-up visits per patient of 1.7 (0.9); 194 (92.8%) patients were women, mean age at diagnosis was 36.4 (14.0) years and disease duration at baseline was 6.5 (6.0) years. Baseline characteristics are depicted in [table 1](#). The correlations between self-efficacy's domains are shown in [table 2](#).

In the multivariable models, a better self-efficacy for managing symptoms, for managing medication and treatment, for managing social interactions and general self-efficacy predicted a better PCS and self-efficacy for managing daily activities, for managing symptoms, for managing medications and treatment and for managing social interactions predicted a better MCS. These univariable and multivariable models are depicted in [table 3](#).

In the alternative models, including each SF-36 domain as the outcome, bodily pain, role emotional and mental health were predicted by the five domains of self-efficacy for managing chronic conditions and the general self-efficacy; role physical was predicted by self-efficacy for managing daily activities, for managing symptoms, for managing medications and treatment, for managing social interactions and general self-efficacy; social functioning was predicted by self-efficacy for managing daily activities, for managing symptoms, for managing emotions, for managing social interactions and general

Table 1 Baseline characteristics of patients from the Almenara Lupus Cohort

Characteristics	N (%) or mean (SD)
Female gender	194 (92.8%)
Ethnicity	
Mestizo	204 (97.6%)
White	2 (1.0%)
Black	3 (1.4%)
Age at diagnosis, years	36.3 (14.0)
Disease duration, years	6.5 (6.0)
SLEDAI-2K	2.2 (3.2)
SDI	1.3 (1.5)
Prednisone daily dose, mg/day	3.2 (3.8)
Antimalarial use	
Never	11 (5.3%)
Past	48 (23.0%)
Current	150 (71.8%)
Immunosuppressive drug use	
Never	45 (21.5%)
Past	60 (28.7%)
Current	104 (49.8%)
SF-36	
PCS	52.0 (22.3)
MCS	53.9 (20.4)
Physical functioning	60.9 (26.4)
Role physical	42.6 (43.8)
Bodily pain	56.6 (25.4)
General health	47.0 (19.6)
Vitality	53.7 (18.1)
Social functioning	60.5 (24.1)
Role emotional	47.8 (42.7)
Mental health	60.7 (17.8)
PROMIS self-efficacy	
Self-efficacy for managing daily activities	45.5 (7.5)
Self-efficacy for managing symptoms	47.7 (8.2)
Self-efficacy for managing medications and treatments	43.9 (7.0)
Self-efficacy for managing emotions	44.6 (8.0)
Self-efficacy for managing social interactions	42.5 (7.9)
General self-efficacy	47.2 (10.4)
MCS, mental component summary; PCS, physical component summary; PROMIS, Patient-Reported Outcomes Measurement Information System; SDI, Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index; SF-36, Short-Form 36; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K.	

Table 2 Correlation between PROMIS self-efficacy's domains

	Self-efficacy for managing daily activities	Self-efficacy for managing symptoms	Self-efficacy for managing medications and treatments	Self-efficacy for managing emotions	Self-efficacy for managing social interactions	General self-efficacy
	Rho (p value)	Rho (p value)	Rho (p value)	Rho (p value)	Rho (p value)	Rho (p value)
Self-efficacy for managing daily activities	X					
Self-efficacy for managing symptoms	0.702 (<0.001)	X				
Self-efficacy for managing medications and treatments	0.439 (<0.001)	0.573 (<0.001)	X			
Self-efficacy for managing emotions	0.617 (<0.001)	0.645 (<0.001)	0.435 (<0.001)	X		
Self-efficacy for managing social interactions	0.453 (<0.001)	0.648 (<0.001)	0.487 (<0.001)	0.544 (<0.001)	X	
General self-efficacy	0.753 (<0.001)	0.706 (<0.001)	0.507 (<0.001)	0.734 (<0.001)	0.506 (<0.001)	X

PROMIS, Patient-Reported Outcomes Measurement Information System.

self-efficacy; general health was predicted by self-efficacy for managing daily activities, for managing symptoms, for managing social interactions and general self-efficacy; physical functioning was predicted by self-efficacy for managing daily activities and for managing social interactions; finally, vitality was not predicted by any of the self-efficacy domains; these data are depicted in [tables 4 and 5](#).

DISCUSSION

In this primarily Mestizo prevalent lupus cohort, a better self-efficacy was associated with a better HRQoL, independently of the other well-known risk factors for it.

We have included the five domains of the PROMIS self-efficacy and the PROMIS general self-efficacy which correlated with each other; however, it is important to point out that these domains evaluate different aspects of self-efficacy, and that probably explains the differences on their impact on HRQoL. For example, those domains related to physical activities were more influenced by self-efficacy domains associated with activities (managing daily activities or managing social interactions) than those associated with emotions or treatment. And for the MCS, it was influenced by all the components of PROMIS self-efficacy except for self-efficacy for managing emotions, and general self-efficacy; role emotional and mental health were influenced by all the components of PROMIS self-efficacy and the PROMIS general self-efficacy, whereas social functioning was influenced by all the components of PROMIS self-efficacy and the PROMIS general self-efficacy except for self-efficacy for managing medications and treatment. The lack of association between vitality and self-efficacy suggests that other factors could be impacting on vitality, like anxiety or depression. These results are consistent

with previous reports that found different predictors for those domains related to physical activities and mental health.^{6 16–18}

In a cross-sectional analysis of the Georgia Lupus Registry, which included 699 patients, symptoms self-efficacy was associated with lower fatigue and pain interference, but treatment self-efficacy did not remain associated in the multivariable model.¹⁹

In a longitudinal Italian study, which included 162 patients with SLE, a better self-efficacy predicted a better HRQoL measured with the lupus PRO (LupusPRO).²⁰ However, these authors used the self-efficacy for managing chronic disease six-items which is a global scale while we have used six domains for self-efficacy; furthermore, they used the global score of the LupusPRO whereas we used the main components and all domains of the SF-36. Our approach has more granularity and considers more domains which can have different predictors. This is important, as we are showing in this study that the association between self-efficacy and HRQoL varies across the domains for both outcomes.

In 30 African-American patients with SLE from the Medical University of South Carolina, the intervention 'Better Choices, Better Health' Chronic Disease Self-Management Programme was performed. This programme covers techniques to deal with problems such as frustration, fatigue, pain and isolation, appropriate exercise for maintaining and improving strength, flexibility and endurance, appropriate use of medications, communicating effectively with family, friends and health professionals, nutrition and how to evaluate new treatments. This programme improved self-efficacy as well as improved fatigue, depression, social/role activities limitations and health distress, suggesting these outcomes are inter-related, and potentially modifiable.²¹ Similar results

Table 3 Predictive value of PROMIS self-efficacy on HRQoL in patients from the Almenara Lupus Cohort

	PCS			MCS				
	Univariable model		Multivariable model	Univariable model		Multivariable model		
	B (SE)	P value	B (SE)	p value	B (SE)	p value		
Self-efficacy for managing daily activities	1.59 (0.13)	<0.001	0.22 (0.13)	0.091	1.44 (0.13)	<0.001	0.39 (0.13)	0.002
Self-efficacy for managing symptoms	1.26 (0.14)	<0.001	0.25 (0.11)	0.021	1.19 (0.13)	<0.001	0.32 (0.12)	0.006
Self-efficacy for managing medications and treatment*	0.71 (0.17)	<0.001	0.20 (0.10)	0.046	0.65 (0.16)	<0.001	0.24 (0.10)	0.016
Self-efficacy for managing emotions	0.99 (0.16)	<0.001	0.12 (0.11)	0.257	1.05 (0.15)	<0.001	0.17 (0.11)	0.161
Self-efficacy for managing social interactions	0.77 (0.15)	<0.001	0.27 (0.09)	0.002	0.86 (0.14)	<0.001	0.37 (0.10)	<0.001
General self-efficacy	0.98 (0.11)	<0.001	0.18 (0.08)	0.037	0.92 (0.11)	<0.001	0.20 (0.10)	0.051

Adjusted for age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/American College of Rheumatology Damage Index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and the PCS or MCS in the previous visit.

Values in bold are those that are statistically significant.

*One patient was excluded as she was not taking any medication during her follow-up.

HRQoL, health-related quality of life; MCS, mental component summary; PCS, physical component summary; PROMIS, Patient-Reported Outcomes Measurement Information System; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K; SLICC, Systemic Lupus International Collaborating Clinics.

Table 4 Predictive value of PROMIS self-efficacy on HRQoL in patients from the Almenara Lupus Cohort

	Physical functioning		Role physical		Bodily pain		General health	
	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value
	Self-efficacy for managing daily activities	0.34 (0.16)	0.036	0.84 (0.31)	0.007	0.51 (0.16)	0.001	0.47 (0.14)
Self-efficacy for managing symptoms	0.26 (0.13)	0.053	0.80 (0.27)	0.003	0.47 (0.14)	<0.001	0.32 (0.12)	0.006
Self-efficacy for managing medications and treatment*	0.15 (0.14)	0.275	0.71 (0.29)	0.015	0.28 (0.14)	0.045	0.22 (0.12)	0.072
Self-efficacy for managing emotions	0.16 (0.11)	0.177	0.45 (0.28)	0.108	0.38 (0.14)	0.008	0.21 (0.11)	0.066
Self-efficacy for managing social interactions	0.25 (0.11)	0.030	0.65 (0.26)	0.012	0.41 (0.14)	0.002	0.33 (0.10)	0.002
General self-efficacy	0.18 (0.10)	0.081	0.62 (0.21)	0.003	0.32 (0.11)	0.003	0.54 (0.06)	0.007

Adjusted for age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/American College of Rheumatology Damage Index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and the same domain in the previous visit.

Values in bold are those that are statistically significant.

*One patient was excluded as she was not taking any medication during her follow-up.

HRQoL, health-related quality of life; PROMIS, Patient-Reported Outcomes Measurement Information System; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K; SLICC, Systemic Lupus International Collaborating Clinics.

Table 5 The predictive value of PROMIS self-efficacy on HRQoL in patients from the Almenara Lupus Cohort

	Vitality		Social functioning		Role emotional		Mental health	
	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value
Self-efficacy for managing daily activities	0.14 (0.11)	0.204	0.71 (0.15)	<0.001	1.26 (0.32)	<0.001	0.35 (0.10)	<0.001
Self-efficacy for managing symptoms	0.12 (0.11)	0.286	0.55 (0.14)	<0.001	0.91 (0.27)	<0.001	0.40 (0.09)	<0.001
Self-efficacy for managing medications and treatment*	0.04 (0.10)	0.684	0.19 (0.14)	0.162	0.82 (0.30)	0.006	0.27 (0.10)	0.004
Self-efficacy for managing emotions	0.13 (0.10)	0.199	0.55 (0.16)	<0.001	0.60 (0.28)	0.032	0.25 (0.10)	0.015
Self-efficacy for managing social interactions	0.20 (0.12)	0.086	0.53 (0.14)	<0.001	0.88 (0.27)	0.001	0.40 (0.11)	<0.001
General self-efficacy	0.08 (0.08)	0.371	0.39 (0.12)	0.001	0.68 (0.23)	0.003	0.24 (0.09)	0.006

Adjusted for age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/American College of Rheumatology Damage Index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and the same domain in the previous visit.

Values in bold are those that are statistically significant.

*Only patients taking at least one medication were included in these analyses.

HRQoL, health-related quality of life; PROMIS, Patient-Reported Outcomes Measurement Information System; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K; SLICC, Systemic Lupus International Collaborating Clinics.

were found by the same group when peer mentoring was proposed to improve self-management of the disease.²²

Similarly, 23 Irish women with SLE received an educational programme including fatigue management, pain management, exercise, joint protection, stress management and nutrition to facilitate the application of self-management skills to promote behavioural changes. This programme was associated with an improvement on depression, and some domains of the LupusQoL (physical health, burden to others and fatigue), but not with the other domains.²³

In Canada, a web-based programme increased self-efficacy, but not in the activation (which measures the individual's level of confidence, beliefs, knowledge and skills for managing one's health) of the patients,²⁴ reinforcing the idea that self-efficacy can be improved by educational programmes. The impact of this self-management programme was higher in those with a low activation level at baseline; however, the uptake and retained engagement with the programme was suboptimal, suggesting that external support or longer periods are required to engage patients in a more sustained manner.²⁴

In a systematic review which included 11 studies of patients with rheumatoid arthritis, a better self-efficacy was associated with a better HRQoL, goal achievement, physical activity participation, problem-solving coping, acceptance of illness but also with lower pain intensity depressive symptoms and anxiety.²⁵ Similarly, in non-autoimmune diseases, like chronic obstructive pulmonary disease²⁶ or diabetes,²⁷ a better self-efficacy has been found to be associated with a better HRQoL. Taking together the data from our study and those from the literature, reinforce the relevance of including self-efficacy as a potential modifiable factor in chronic diseases like SLE.

Our study has some limitations; first, as this is a prevalent cohort, we cannot exclude the impact of disease characteristics before the baseline visit. Second, we cannot exclude the impact of other characteristics that could affect self-efficacy and/or HRQoL like social/family support, personal belief, among others. The main strength of this study is sample size. This is the largest study that evaluates longitudinally the association between self-efficacy and HRQoL in patients with SLE.

In conclusion, a better self-efficacy is predictive of a subsequent better HRQoL, even after adjusting for possible confounders. These results should encourage clinicians to develop strategies to improve self-efficacy in patients with SLE.

Author affiliations

¹Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSaalud, Lima, Peru

²Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru

³Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru

⁴Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Ica, Peru

⁵Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru

⁶Max E. Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

⁷School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

Twitter Manuel Francisco Ugarte-Gil @mugartegil

Contributors All authors were involved in drafting or revising this article critically for important intellectual content, and all authors approved the final version to be published. MFU-G has full access to all of the data from the study and takes responsibility for their integrity and the accuracy of the analyses performed. MFU-G is the guarantor of the study.

Funding These analyses were done as a part of a Research Grant from Janssen. Additionally, the Almenara Lupus Cohort has been partially supported by Institutional grants from EsSalud (1483-GCGP-ESSALUD-2013, 1733-GCGP-ESSALUD-2014 and the 2015 Kaelin Prize 04-IETSI-ESALUD-2016), from the Pan American League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize and the 2018 H. Ralph Schumacher MD/JCR/PANLAR Prize) and from the Fundación Instituto Hipólito Unanue, Lima, Perú.

Competing interests MFU-G has grant support from Janssen and Pfizer and he has been speaker for GSK; RVG-C has grant support from Pfizer; CR-S and VRP-Q have grant support from Janssen. All other authors declare to have no conflicts of interest.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the 'Methods' section for further details.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the Hospital Guillermo Almenara Irigoyen institutional review board (3474-OCID-G-RAA-ESSALUD-11, 271-CEI-CIDG-RAA-ESSALUD-13, 302-CEI-ICD-G-RAA-14, 3027-OCID-G-RAA-ESSALUD-15 and 4072-OCID-G-HNGAI-ESSALUD-2017). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Manuel Francisco Ugarte-Gil <http://orcid.org/0000-0003-1728-1999>

Cristina Reátegui-Sokolova <http://orcid.org/0000-0003-3421-2717>

Victor Román Pimentel-Quiroz <http://orcid.org/0000-0002-3638-7054>

REFERENCES

- Clark NM, Dodge JA. Exploring self-efficacy as a predictor of disease management. *Health Educ Behav* 1999;26:72–89.
- Sood P, Romero S, Velozo C, *et al*. Defining self-efficacy for managing chronic conditions and identifying priority sub-domains: a web-based delphi technique. *Arch Phys Med Rehabil* 2015;96:e43.
- Cella D, Riley W, Stone A, *et al*. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J Clin Epidemiol* 2010;63:1179–94.
- Gruber-Baldini AL, Velozo C, Romero S, *et al*. Validation of the PROMIS® measures of self-efficacy for managing chronic conditions [Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation]. *Qual Life Res* 2017;26:1915–24.
- Salsman JM, Schalet BD, Merluzzi TV, *et al*. Calibration and initial validation of a general self-efficacy item bank and short form for the NIH PROMIS® [Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation]. *Qual Life Res* 2019;28:2513–23.
- Elera-Fitzcarrald C, Fuentes A, González LA, *et al*. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. *Expert Rev Clin Immunol* 2018;14:915–31.
- Lin CH, Liu CY, Huang CC, *et al*. Frailty and quality of life among older adults in communities: the mediation effects of daily physical activity and healthy life self-efficacy. *Geriatrics (Basel)* 2022;7:125.
- Shulman LM, Velozo C, Romero S, *et al*. Comparative study of PROMIS® self-efficacy for managing chronic conditions across chronic neurologic disorders [Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation]. *Qual Life Res* 2019;28:1893–901.
- Ugarte-Gil MF, Gamboa-Cárdenas RV, Zevallos F, *et al*. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. *Lupus* 2014;23:969–74.
- Hochberg MC. Updating the American college of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
- Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29:288–91.
- Gladman D, Ginzler E, Goldsmith C, *et al*. The development and initial validation of the systemic lupus international collaborating clinics/American College of rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996;39:363–9.
- Ware JE, Sherbourne CD. The mos 36-item short-form health survey (SF-36). *Medical Care* 1992;30:473–83.
- World Health Organization. Process of translation and adaptation of instruments. Available: <https://www.google.com.pe/url?sa=t&rc=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKewjKmZfOy9H8AhWQKLkGHRd0AzcQFnoECBMQAw&url=https%3A%2F%2Fwww.mhinnovation.net%2Fsites%2Fdefault%2Ffiles%2Ffiles%2FWHO%2520Guidelines%2520on%2520Translation%2520and> [Accessed 18 Jan 2023].
- Green SB. How many subjects does it take to do a regression analysis. *Multivariate Behav Res* 1991;26:499–510.
- Klein R, Moghadam-Kia S, Taylor L, *et al*. Quality of life in cutaneous lupus erythematosus. *J Am Acad Dermatol* 2011;64:849–58.
- Jolly M, Toloza S, Goker B, *et al*. Disease-specific quality of life in patients with lupus nephritis. *Lupus* 2018;27:257–64.
- Ishiguro M, Hashizume H, Ikeda T, *et al*. Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan. *Lupus* 2014;23:93–101.
- Drenkard C, Easley K, Bao G, *et al*. Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education. *Lupus Sci Med* 2022;9:e000566.
- Mazzoni D, Cicognani E, Prati G. Health-related quality of life in systemic lupus erythematosus: a longitudinal study on the impact of problematic support and self-efficacy. *Lupus* 2017;26:125–31.
- Williams EM, Penfield M, Kamen D, *et al*. An intervention to reduce psychosocial and biological indicators of stress in African American lupus patients: the balancing lupus experiences with stress strategies study. *Open J Prev Med* 2014;4:22–31.
- Williams EM, Hyer JM, Viswanathan R, *et al*. Peer-to-peer mentoring for African American women with lupus: a feasibility pilot. *Arthritis Care Res (Hoboken)* 2018;70:908–17.
- O'Riordan R, Doran M, Connolly D. Fatigue and activity management education for individuals with systemic lupus erythematosus. *Occup Ther Int* 2017;2017:4530104.
- Fortin PR, Neville C, Julien A-S, *et al*. Measuring the impact of mylupusguide in canada: results of a randomized controlled study. *Arthritis Care Res (Hoboken)* 2022;28.
- Martinez-Calderon J PT, MSc, Meeus M PT, PhD, Struyf F PT, PhD, *et al*. The role of self-efficacy in pain intensity, function, psychological factors, health behaviors, and quality of life in people with rheumatoid arthritis: a systematic review. *Physiother Theory Pract* 2020;36:21–37.
- Selzler AM, Habash R, Robson L, *et al*. Self-efficacy and health-related quality of life in chronic obstructive pulmonary disease: a meta-analysis. *Patient Educ Couns* 2020;103:682–92.
- Hamidi S, Gholamnezhad Z, Kasraie N, *et al*. The effects of self-efficacy and physical activity improving methods on the quality of life in patients with diabetes: a systematic review. *J Diabetes Res* 2022;2022:2884933.